Key result
Pre-treatment with renin-angiotensin system inhibitors (enalapril or TCV-116) completely suppressed LPS-induced renal IL-6 and TNF-alpha mRNA levels in rats (P<0.05).
Why the study?
Does pre-treatment with renin-angiotensin system inhibitors prevent endotoxin-induced renal TNF-alpha and IL-6 mRNA production in rats?
Population
Four-week-old Wistar rats and rats infused with Ang II
Comparison
Pre-treatment with angiotensin-converting enzyme… vs Control (LPS without inhibitor)
Design
Preclinical
Follow-up
2 or 4 hours
Authors
Loading...
Should not change practice; leaves open whether RAS inhibitors mitigate cytokine-driven renal injury in patients.
Does pre-treatment with renin-angiotensin system inhibitors prevent endotoxin-induced renal TNF-alpha and IL-6 mRNA production in rats?
p-value: p=<0.05
A single dose of renin-angiotensin system inhibitors completely suppressed endotoxin-induced renal IL-6 and TNF-alpha production in a rat model, suggesting a potential protective effect against cytokine-induced renal damage.
Niimi et al. (2002) studied Endotoxemia. Enalapril or TCV-116 vs. Control was evaluated on Renal TNF-alpha and IL-6 mRNA levels (p=<0.05). Pre-treatment with renin-angiotensin system inhibitors (enalapril or TCV-116) completely suppressed LPS-induced renal IL-6 and TNF-alpha mRNA levels in rats (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: